<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lb Pharmaceuticals Inc Common Stock — News on 6ix</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock</link>
<description>Latest news and press releases for Lb Pharmaceuticals Inc Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lb-pharmaceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-publication-in-jama-psychiatry-of-results-from-phase-2-nova-1-trial-of-lb-102-in-schizophrenia</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-publication-in-jama-psychiatry-of-results-from-phase-2-nova-1-trial-of-lb-102-in-schizophrenia</guid>
<pubDate>Wed, 22 Apr 2026 20:05:00 GMT</pubDate>
<description>Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced t</description>
</item>
<item>
<title>LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-at-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-at-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical</description>
</item>
<item>
<title>LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-presents-new-analysis-from-the-phase-2-nova-1-trial-highlighting-lb-102s-potential-impact-on-cognitive-performance-at-the-2026-annual-congress-of-the-schizophrenia-international-research-society-sirs</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-presents-new-analysis-from-the-phase-2-nova-1-trial-highlighting-lb-102s-potential-impact-on-cognitive-performance-at-the-2026-annual-congress-of-the-schizophrenia-international-research-society-sirs</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia NEW YORK, March</description>
</item>
<item>
<title>LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple</description>
</item>
<item>
<title>LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-initiates-pivotal-phase-3-trial-nova-2-for-lb-102-in-patients-with-schizophrenia</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-initiates-pivotal-phase-3-trial-nova-2-for-lb-102-in-patients-with-schizophrenia</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to</description>
</item>
<item>
<title>LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-randd-biotech-executive-robert-lenz-md-phd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-randd-biotech-executive-robert-lenz-md-phd-to-board-of-directors</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB</description>
</item>
<item>
<title>LB Pharmaceuticals to Participate in Upcoming March Investor Events</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-to-participate-in-upcoming-march-investor-events-135</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-to-participate-in-upcoming-march-investor-events-135</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical</description>
</item>
<item>
<title>LB Pharmaceuticals Announces $100.0 Million Private Placement</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-100-0-130000390</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-100-0-130000390</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional inv</description>
</item>
<item>
<title>LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-initiates-phase-2-130000284</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-initiates-phase-2-130000284</guid>
<pubDate>Mon, 26 Jan 2026 13:00:00 GMT</pubDate>
<description>Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in</description>
</item>
<item>
<title>LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-minako-pazdera-130000135</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-minako-pazdera-130000135</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactio</description>
</item>
<item>
<title>LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-inducement-grant-210500715</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-inducement-grant-210500715</guid>
<pubDate>Mon, 12 Jan 2026 21:05:00 GMT</pubDate>
<description>NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate Affairs and Lindsay Beaupre, the new Senior Vice President of People and Culture of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on January 9, 2026, pursuant</description>
</item>
<item>
<title>LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-strengthens-leadership-team-120000335</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-strengthens-leadership-team-120000335</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. “We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals,” said</description>
</item>
<item>
<title>LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-added-russell-2000-130000302</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-added-russell-2000-130000302</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 2025 Russell indexes reconstitution. “Inclusion in the Russell 2000 and Russell 3000 indices represents an important milestone following our recent initial public offering,” said He</description>
</item>
<item>
<title>LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-piper-130000508</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-piper-130000508</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference in New York, NY on Wednesday, December 3, 2025, at 9:30 a.m. ET. A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/, where a r</description>
</item>
<item>
<title>LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-kaya-pai-130000372</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-kaya-pai-130000372</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensi</description>
</item>
<item>
<title>LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-stifel-210500210</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-announces-presentation-stifel-210500210</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference in New York, NY on Thursday, November 13, 2025, at 9:20 a.m. ET. A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/, where a replay of the w</description>
</item>
<item>
<title>LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-3q-2025-130000245</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-reports-3q-2025-130000245</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced financial results for the third quarter ended on September 30, 2025 and provided recent corporate updates. “Following our recent initial public offering, we are well-positioned to continue executing on our strategy to advance LB-102 into a Phase 3 trial in acute schizophrenia, as well as a Phase 2 trial in bipolar depression,” said Heather Turner, Chief Execut</description>
</item>
<item>
<title>LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-james-rawls-123000985</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-appoints-james-rawls-123000985</guid>
<pubDate>Tue, 14 Oct 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. Rawls has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric diseases. “Dr. Rawls has a remarkable depth of regulatory</description>
</item>
<item>
<title>LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-present-three-posters-123000626</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-present-three-posters-123000626</guid>
<pubDate>Mon, 06 Oct 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA1 clinical trial of LB-102 in acute schizophrenia will be presented at the 38th European College of Neuropsychopharmacology (“ECNP”) Congress, taking place in Amsterdam, The Netherlands, from October 11-14, 2025. Among the presentations will be an analysis evaluating the eff</description>
</item>
<item>
<title>LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani</title>
<link>https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-strengthens-board-directors-123000009</link>
<guid isPermaLink="true">https://6ix.com/company/lb-pharmaceuticals-inc-common-stock/news/lb-pharmaceuticals-strengthens-board-directors-123000009</guid>
<pubDate>Thu, 25 Sep 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company adva</description>
</item>
</channel>
</rss>